1. Global Epidemiologic Variability of EGFR Mutation NSCLC Keunchil Park, MD, PhD Professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center Seoul, Korea Epidemiologic studies can be subject to selection bias. Real-life data may differ.

2. EGFR Epidemiologic Studies in Asia PIONEER [a] (China, Taiwan, Vietnam, Thailand …) Malaysia [b] (including ethnic Chinese, Malay, Indians)Korea [c] Japan [d] Total no.1450812575308 EGFR testScorpion ARMSSanger or QIAGENSangerPNA-LNA Female43%49%48%33% Adenocarcinoma100% 85%79% Never-smoker53%59%54%31%* *Less than 20 pack-years or never smokers a. Yang PC, et al. ASCO 2012. Abstract 1534. b. Liam CK, et al. J Thorac Oncol. 2013;8(6):766-772. c. Choi YL, et al. PLoS One. 2013;8(2):e56011. d. Tanaka T, et al. Int J Cancer. 2010;126(3):651-655. ARMS = amplification-refractory mutation system; EGFR = epidermal growth factor receptor; PNA-LNA = peptide nucleic acid-locked nucleic acid

3. EGFR Mutation Rates in Asia PIONEER (single study) [a] a. Yang PC, et al. ASCO 2012. Abstract 1534. b. Liam CK, et al. J Thorac Oncol. 2013;8(6):766-772. c. Choi YL, et al. PLoS One. 2013;8(2):e56011. d. Tanaka T, et al. Int J Cancer. 2010;126(3):651-655.

4. EGFR Epidemiologic Studies in Asia PIONEER [a] (China, Taiwan, Vietnam, Thailand …) Malaysia [b] (including ethnic Chinese, Malay, Indians)Korea [c] Japan [d] Total no.1450812575308 EGFR testScorpion ARMSSanger or QIAGENSangerPNA-LNA Female43%49%48%33% Adenocarcino ma 100% 85%79% Never-smoker53%59%54%31%* *Less than 20 pack-years or never smokers a. Yang PC, et al. ASCO 2012. Abstract 1534. b. Liam CK, et al. J Thorac Oncol. 2013;8(6):766-772. c. Choi YL, et al. PLoS One. 2013;8(2):e56011. d. Tanaka T, et al. Int J Cancer. 2010;126(3):651-655.

5. Predictors of EGFR Mutation EGFR Mutation Rates PIONEER [a] Malaysia [b] Korea [c] Japan [c] Female vs male (%) 61 vs 4453 vs 2845 vs 2959 vs 25 Never or light smoker vs heavy smoker (%) 61 vs 3155 vs 2140 vs 2739 vs 22 a. Yang PC, et al. ASCO 2012. Abstract 1534. b. Liam CK, et al. J Thorac Oncol. 2013;8(6):766-772. c. Choi YL, et al. PLoS One. 2013;8(2):e56011. d. Tanaka T, et al. Int J Cancer. 2010;126(3):651-655.

6. EGFR Mutation Rates in the West a. Rosell R, et al. N Engl J Med. 2009;361(10):958-967; b. de Mello RA, et al. Tumour Biol. 2012;33(6):2061-2068; c. Smits AJ, et al. Cell Oncol (Dordr). 2012;35(3):189-196; d. Boch C, et al. BMJ Open. 2013;3(4):e002560; e. Cote ML, et al. Thorac Oncol. 2011;6(3):627-630.

7. Temporal Trends in EGFR Mutation Test in Korea Phase 1Phase 2Phase 3 Time period Jan. 2007-July 2008Aug. 2008-Sep. 2009Oct. 2009-July 2010 Choi YL, et al. PLoS One. 2013;8(2):e56011. P =.001 P <.001

8. Thank you for participating in this activity.